سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

Synergic hepatotoxicity of Remdesivir and Frankincense: A SARS-CoV-2 Patient Report

Publish Year: 1401
Type: Conference paper
Language: English
View: 283

This Paper With 5 Page And PDF Format Ready To Download

Export:

Link to this Paper:

Document National Code:

MPSA13_012

Index date: 1 October 2022

Synergic hepatotoxicity of Remdesivir and Frankincense: A SARS-CoV-2 Patient Report abstract

Remdesivir is an effective component of the therapeutic regime for SARS-CoV-2 pneumonia that the hepatotoxic side effect limits the continuous administration of drugs. In the Middle East, frankincense, a natural product is used as a complementary treatment for SARS-CoV-2. Here, we report a clinical case with a synergic hepatotoxicity finding receiving remdesivir and frankincense simultaneously. A male 59-year-old admitted with eighty present lung involvements and reduced oxygen saturation. The patient without liver disorder history showed an elevation in the serum liver injury biomarkers leading to halt in remdesivir administration. The self-medication of frankincense has been considered as underlying causes exaggerated hepatotoxicity in this case. Frankincense withdrawing reduced the liver biomarkers significantly in spite of administrating the remdesiver in 5th and 6th dosage in the next days. We concluded that frankincense exacerbates the hepatotoxic side effect of remdesiver.

Synergic hepatotoxicity of Remdesivir and Frankincense: A SARS-CoV-2 Patient Report Keywords:

Synergic hepatotoxicity of Remdesivir and Frankincense: A SARS-CoV-2 Patient Report authors

Shiva Mehran

Department of Biology, Higher Education Institute of Rabe-Rashidi, Tabriz, Iran

Soroush Ghodratizadeh

Department of Biochemistry, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Zafar Gholinejad

Department of Medical Laboratory Science, Urmia Branch, Islamic Azad University, Urmia, Iran